跳转至内容
Merck
CN

936626

Fmoc-Val-Cit-PAB-PNP

≥95%

别名:

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(4-nitrophenoxy)carbonyl]oxy]methyl]phenyl]-L-ornithinamide (ACI), L-Ornithinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(4-nitrophenoxy)carbonyl]oxy]methyl]phenyl]- (9CI, ACI)

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C40H42N6O10
化学文摘社编号:
863971-53-3
分子量:
766.80
MDL编号:
MFCD22200278
UNSPSC代码:
12352209
NACRES:
NA.22

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

100

方案

≥95%

表单

powder or crystals

颜色

Off White to Yellow to Beige

储存温度

2-8°C

SMILES字符串

C(OC(N[C@H](C(N[C@H](C(NC1=CC=C(COC(OC2=CC=C(N(=O)=O)C=C2)=O)C=C1 )=O)CCCNC(N)=0)=O)C(C)C)=O)C3C=4C(C=5C3-CC-CC5)=CC-CC4

InChI

1S/C40H42N6O10/c1-24(2)35(45-39(50)54-23-33-31-10-5-3-8-29(31)30-9-4-6-11-32(30)33)37(48)44-34(12-7-21-42-38(41)49)36(47)43-26-15-13-25(14-16-26)22-55-40(51)56-28-19-17-27(18-20-28)46(52)53/h3-6,8-11,13-20,24,33-35H,7,12,21-23H2,1-2H3,(H,43,47)(H,44,48)(H,45,50)(H3,41,42,49)/t34-,35-/m0/s1

InChI key

USMYACISHVPTHK-PXLJZGITSA-N

应用

This is a cathepsin cleavable linker used in bioconjugation, specifically in the construction of antibody drug conjugates (ADC & Bioconjugation).

特点和优势

Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC). The Val-Cit is specifically cleaved by cathepsin B. Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers.

其他说明

ADC & Bioconjugation.

Chemical Biology Tools.

http://pubs.rsc.org/en/Content/ArticleLanding/2011/MB/C0MB00074D#!divAbstract

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000305727
0000305729
0000305727
0000305729
0000292072

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Qinhuai Lai et al.
European journal of medicinal chemistry, 199, 112364-112364 (2020-05-14)
Cryptophycin-52 (CR52), a tubulin inhibitor, exhibits promising antitumor activity in vitro (picomolar level) and in mouse xenograft models. However, the narrow therapeutic window in clinical trials limits its further development. Antibody-drug conjugate (ADC), formed by coupling cytotoxic compound (payload) to an
Zixuan Ye et al.
International journal of nanomedicine, 16, 2443-2459 (2021-04-06)
Specific modifications to carriers to achieve targeted delivery of chemotherapeutics into malignant tissues are a critical point for efficient diagnosis and therapy. In this case, bovine serum albumin (BSA) was conjugated with cetuximab-valine-citrulline (vc)-doxorubicin (DOX) to target epidermal growth factor

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持